Atlas Trials

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Clinical trial NCT07492914 · RECRUITING

Trial details

NCT number
NCT07492914
Sponsor
West China Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Head and Neck Squamous Cell Carcinoma
Start date
2026-05-11
Primary completion
2026-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.